866-997-4948(US-Canada Toll Free)

Hand, Foot and Mouth Disease - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 36 Pages

Hand, Foot and Mouth Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H2 2016, provides an overview of the Hand, Foot and Mouth Disease (Infectious Disease) pipeline landscape.

Hand, foot and mouth disease is an illness that causes sores in or on the mouth and on the hands, feet, and legs. Hand, foot and mouth disease (HFMD) is most commonly caused by coxsackievirus A16, a member of the enterovirus family. Symptoms include fever, headache, loss of appetite and ulcers in the throat (including tonsils), mouth, and tongue. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hand, Foot and Mouth Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.Hand, Foot and Mouth Disease.

Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hand, Foot and Mouth Disease (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hand, Foot and Mouth Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hand, Foot and Mouth Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hand, Foot and Mouth Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hand, Foot and Mouth Disease Overview 6
Therapeutics Development 7
Pipeline Products for Hand, Foot and Mouth Disease - Overview 7
Pipeline Products for Hand, Foot and Mouth Disease - Comparative Analysis 8
Hand, Foot and Mouth Disease - Therapeutics under Development by Companies 9
Hand, Foot and Mouth Disease - Therapeutics under Investigation by Universities/Institutes 10
Hand, Foot and Mouth Disease - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hand, Foot and Mouth Disease - Products under Development by Companies 13
Hand, Foot and Mouth Disease - Products under Investigation by Universities/Institutes 14
Hand, Foot and Mouth Disease - Companies Involved in Therapeutics Development 15
CJ HealthCare Corp 15
Sentinext Therapeutics Sdn Bhd 16
Takeda Pharmaceutical Company Ltd 17
Hand, Foot and Mouth Disease - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
(coxsackievirus [serotype A16] + enterovirus [serotype 71]) vaccine - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CJ-40010 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
D-5 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
DC-07090 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Enterovirus [serotype EV-A71] (virus like particle, bivalent) vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
hand, foot and mouth disease (viral like particle, bivalent) vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Inhibit MAP2K1 for Hand, Foot and Mouth Disease - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
TAK-021 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Hand, Foot and Mouth Disease - Dormant Projects 33
Hand, Foot and Mouth Disease - Product Development Milestones 34
Featured News & Press Releases 34
Mar 11, 2012: Inviragen Reports Top-Line Results From Phase I Trial Of INV21 Vaccine For Treatment Of Hand, Foot And Mouth Disease 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables
Number of Products under Development for Hand, Foot and Mouth Disease, H2 2016 7
Number of Products under Development for Hand, Foot and Mouth Disease - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Hand, Foot and Mouth Disease - Pipeline by CJ HealthCare Corp, H2 2016 15
Hand, Foot and Mouth Disease - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2016 16
Hand, Foot and Mouth Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Assessment by Combination Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Hand, Foot and Mouth Disease - Dormant Projects, H2 2016 33

List of Figures
Number of Products under Development for Hand, Foot and Mouth Disease, H2 2016 7
Number of Products under Development for Hand, Foot and Mouth Disease - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Molecule Types, H2 2016 23
Number of Products by Stage and Molecule Types, H2 2016 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *